Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging...
Redeye comments on Avensia’s April and May sales figures.
Magle has announced an update on the ongoing negotiations with its principal bondholders regarding a...
Duni announced that Q2 2026 operating income will fall below market expectations, citing significant...
Yesterday, Bittium received a EUR 14m order from the Finnish Defence Forces for SDR radios to be del...
Despite continued mixed end-markets, we expect that Alcadon will continue on its path of gradually i...
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) ...
Vi inleder bevakning på Amhult 2, ett fastighetsutvecklings och förvaltningsbolag med ett unikt sta...
Redeye updates on Xspray following a management call that provided some clarification on the Nilopki...
Redeye comments on the new investigator-sponsored phase II study in up to 59 current or previous smo...
Yesterday, 2.72m already existing MHP Hotel shares were successfully placed (oversubscribed), equiva...
Yesterday, Bittium announced two significant developments.
We trim 2026E-28E adjusted EBITA by 2% ahead of the Q2 report due on 15 July, mainly due to persiste...
Redeye is encouraged by the progress of the INFLECION program, now entering the next phase, where AA...
* Merchant-first platform in a fragmented Nordic market * Loan book growth transforms volumes into r...
ALL.SPACE has awarded Sivers a USD8.2m production order for Ka-band beamforming ICs, covering volume...
AlzeCure has out-licensed the global rights for Alzstatin ACD680 to Eli Lilly in a deal potentially ...
We expect Duell's sales and earnings to decrease in Q3, its biggest quarter in the year, reflecting ...
Kan bolaget skala upp genom ett skifte i intäktsmixen, eller skapar förvärvsstrategin problem med in...
Redeye comments on the latest funding round of Umecrine, resulting in a significantly lower book val...
